comprehensive -WSS

comprehensive

author：entertainment 2025-10-01 17:06:27 - browse：55

Adam's take main illustration — Molly Ferguson/STAT

It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett syndrome.

The negative study outcome was never in doubt, so the only surprise from Tuesday’s announcement was the company’s lame attempt at damage control. Anavex is a serial dissembler of clinical trial results, so I was expecting better spin. Instead, management barely tried, which tells you the real results from the Rett study must be truly awful.

Anavex shares fell 31% to $6 in early trading. The company’s only drug in clinical development, called blarcamesine, is a zero. Rett is the latest failure, following earlier study failures in Alzheimer’s disease and Parkinson’s disease. Yet even with Tuesday’s drop in share price, Anavex still carries a fully diluted market value of nearly $650 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： UCLA team creates talking throat patch for voice disorders

explore

WSS

Republican states more likely to report Covid vaccine side effects

Multiple sclerosis has subtypes with different best treatments: study

Insurer loopholes limit power of law against surprise medical bills

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Medicare Advantage 2025 payments will dip, Biden administration says

Mass General Brigham physicians react to latest merger step

hotspot

comprehensive

leisure time

Wildfire smoke exposes gaps in outdoor worker protections

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Virginia high school admissions case could be legal follow

Drug companies' payments and gifts affect physicians' prescribing

State Dept. review finds Biden bears some blame for Afghanistan failures

UCLA team creates talking throat patch for voice disorders

Affirmative action in medical school literally saved lives

HHS secretary Becerra pressed on Change HealthCare cyberattack

Dobbs anniversary: the lost opportunity of abortion as health care

Amid AI frenzy, a top HHS official's quest to create safeguards

knowledge

Steward Health Care Massachusetts hospitals face fiscal disaster

HHS secretary Becerra pressed on Change HealthCare cyberattack

Republican states more likely to report Covid vaccine side effects

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Medicare Advantage 2025 payments will dip, Biden administration says

Overprescribed: High cost isn't America's only drug problem

explore

explore

hotspot

explore